Bharat Bio's COVAXIN: Ten takeaways from successful animal trials of the experimental COVID-19 vaccine
The animal trials demonstrate that COVAXIN protected against SARS-CoV-2, and amped up two kinds of antibodies needed for a strong immune response against the virus.
India records 83,809 new cases, COVID-19 tally crosses 49 lakh; 5 states account for 60% of active cases, says health ministry
India's COVID-19 caseload rose to 49,30,236 while the toll climbed to 80,776 with 1,054 people succumbing to the disease in 24 hours, the health ministry's data showed.
Coronavirus vaccine may hit Indian market by first quarter of 2021, says health minister Harsh Vardhan
Two homegrown vaccine candidates — Covaxin by Bharat Biotech and ZyCOV-D by Zydus Cadila — have almost finished the phase II clinical trials
Emerging landscape of COVID-19 vaccines in India, 14 Aug: Bharat Bio, Zydus move to Phase 2; Biological E, Bayor College tie up for COVID-19 vaccine
Over a dozen Indian companies are in partnership with other firms and institutes to bring a preventive vaccine into global markets by 2021.
Serum Institute of India has been chosen by Oxford University and its partner AstraZeneca to manufacture the COVID-19 vaccine
Over 3,500 volunteers have registered themselves for the trial at AIIMS this week, of whom the screening of 22 people is underway, doctors said
Covaxin, Bharat Biotech's COVID-19 vaccine candidate, has been developed in collaboration with the ICMR and NIV
Race for COVID-19 vaccine: Covaxin and ZyCoV-D begin human trials in India, Moderna publishes preliminary data from phase 1
While Covaxin is an inactivated whole-virion vaccine, ZyCoV-D is a DNA-plasmid based vaccine.
Indian pharma well-placed to develop, manufacture COVID-19 vaccine; but it must guard against rushing trials
Some experts told Firstpost that the government is willing to fast-track regulation, which is a risk they are willing to take, after completing "due protocols to check the safety of the drug"
COVAXIN controversy: Doctors in trial sites chosen by ICMR say human trials can’t be fast forwarded, anticipate 6-month observation period
Hyderabad-based Bharat Biotech received approval from the Central Drugs Standard Control Organisation (CDSCO) to begin human trials of COVAXIN last week. The vaccine has been developed in collaboration with the ICMR and National Institute of Virology in Pune.
Human trials of Indian COVID-19 vaccine candidates mark ‘beginning of pandemic’s end’, writes Vigyan Parisar scientist
Aiming to launch a COVID-19 vaccine by 15 August, ICMR had written to select medical institutions to expedite clinical trials for the candidate COVAXIN
PIB uploads article claiming none of six Indian companies working on COVID-19 vaccine will have it ready before 2021, later removes mention of year
The statement deleted from the article on PIB contradicted the Indian Council of Medical Research's plan to launch a vaccine by 15 August this year.
Day after ICMR's clarification on coronavirus vaccine, IASc calls timeline 'unprecedented and unfeasible'
A day after the ICMR announced that it aims to launch a COVID-19 vaccine by 15 August, it issued a clarification saying the process to expedite trials was in accordance with norms
While the ICMR has said it is important to expedite the clinical trials for a promising indigenous vaccine in the public interest and that all other vaccine candidates across the globe have been similarly fast-tracked, scientists in one voice have cautioned against being over-optimistic
Coronavirus Updates: Confirmed cases in Maharashtra cross two lakh with 7,074 new infections reported today; toll reaches 8,671
Coronavirus Updates: According to a state health department bulletin, over 1.98 lakh patients have been discharged till date and the recovery rate stands at 54.02 percent
COVAXIN controversy: Bharat Biotech-ICMR readying a COVID-19 vaccine in 45 days baffles reason, ignores safety concerns, says bioethicist
Dr Anant Bhan, a researcher in global health, bioethics and health policy and former president of International Association of Bioethics, spoke to Firstpost about the "extreme urgency" shown by ICMR in developing India's COVID-19 vaccine, COVAXIN, by 15 August
A virologist said that a vaccine normally takes at least 12-18 months to pass all necessary clinical trial phases while the company developing it has just over a month to wrap up everything
Bharat Biotech has passed mandated protocols, animal testing and is now in clinical development of Covid vaccine, Dr Krishna Ella tells Firstpost
Hyderabad-based Bharat Biotech, one of seven Indian companies involved in the indigenous production of a vaccine for the novel coronavirus, received the green signal from the Central Drugs Standard Control Organisation (CDSCO) to begin human trials of 'Covaxin' last week.
COVID-19 vaccine: ICMR urges institutes chosen for Bharat Biotech's COVAXIN to complete recruitment for human trials by 7 July
The ICMR envisages launching the vaccine for public health use by 15 August after completion of all clinical trials, as per a letter to institutions conducting trials.
Coronavirus Updates: Centre tells states to enable all doctors, including private practitioners, to prescribe COVID-19 tests
Coronavirus LIVE Updates: Union health secretary Preeti Sudan and ICMR director general Balram Bhargava on Wednesday wrote to state governments and Union territories to increase testing.